Self-assembling cyclopeptide-dye compounds, formulations thereof, and uses thereof
US-2020023081-A1 · Jan 23, 2020 · US
US12358952B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12358952-B2 |
| Application number | US-202218272674-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 19, 2022 |
| Priority date | Jan 19, 2021 |
| Publication date | Jul 15, 2025 |
| Grant date | Jul 15, 2025 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The invention described herein includes a novel platform for the development of novel shapeshifting drug-like compounds that overcome physical mass limitations as they possess the ability to interconvert internally and spontaneously, i.e., shapeshift, between multiple chemical structures with varying pharmacophore properties. In one preferred embodiment, the invention include systems, methods, and compositions for the synthesis of novel bullvalene amino acid (Bvas) compounds that may further be incorporated into Shape Shifting Cyclic Peptides (SSCP) with varying pharmacophore properties and their use as novel therapeutic compounds.
Opening claim text (preview).
What is claimed is: 1. A di-substituted bullvalene amino acid (Bva) composition according to Formula (I-A): wherein R is H, a protecting group, Boc, or Fmoc. 2. A tri-substituted bullvalene amino acid (Bva) composition according to Formula (I-B): wherein R is H, a protecting group, Boc, or Fmoc; and wherein comprises a canonical and/or non-canonical side-chain optionally selected from the group consisting of: 3. The composition of claim 1 , wherein the composition comprises an Fmoc-Bva and is further incorporated into a Fmoc-solid phase peptide synthesis (SPPS) system forming a linear peptide coupled with said Fmoc-Bva which can be cyclized forming a Shape Shifting Cyclic Peptide (SSCP). 4. The composition of claim 2 , wherein the composition comprises an Fmoc-Bva and is further incorporated into a Fmoc-solid phase peptide synthesis (SPPS) system forming a linear peptide coupled with said Fmoc-Bva which can be cyclized forming a Shape Shifting Cyclic Peptide (SSCP).
on carriers {(C07K1/003, C07K1/006 take precedence)} · CPC title
of peptides containing derivatised side chain amino acids · CPC title
Design of libraries · CPC title
the cyclisation not occurring through 2,4-diamino-butanoic acid · CPC title
by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.